Enliven Therapeutics, Inc. (NASDAQ: ELVN) has announced the pricing of its underwritten public offering of 8,394,737 shares of its common stock at a price to the public of $19.66 per share. Additionally, the company is offering pre-funded warrants to purchase up to 1,780,263 shares of its common stock at a price to the public of $19.659 per pre-funded warrant.
The gross proceeds from the offering are expected to be approximately $200 million before deducting underwriting discounts and commissions as well as other offering expenses. The offering is anticipated to close on or about June 16, 2025, subject to the satisfaction of customary closing conditions.
Enliven has also granted the underwriters a 30-day option to purchase up to an additional 1,526,250 shares of its common stock at the public offering price, less the underwriting discounts and commissions. Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho are acting as joint book-running managers for the offering, with Lifesci Capital serving as the lead manager.
The offering is being conducted pursuant to a registration statement on Form S-3, including a base prospectus, which was previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC), as well as a related registration statement filed with the SEC on June 13, 2025, pursuant to Rule 462(b) under the Securities Act of 1933.
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics aimed at addressing unmet needs with a precision oncology approach. The company is based in Boulder, Colorado. As a result of these announcements, the company's shares have moved 11.45% on the market, and are now trading at a price of $21.91. For more information, read the company's full 8-K submission here.
